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ABSTRACT   
 
 Parkinson’s disease (PD) is a neurodegenerative disorder associated with motor 
disturbance and non-motor symptoms (NMS). Although NMS such as sleep and circadian 
disruption, cognitive impairment, and mood disturbance are prevalent and debilitating, 
treatments are limited, owing to lack of knowledge about their etiologies and interactions. 
This project comprised two studies of NMS in mild to moderate idiopathic PD without 
dementia.  
The hypothesis of Study 1 was that disruption of rest-activity circadian rhythm 
contributes to cognitive impairment in PD independently of sleep disruption. Thirty-five 
participants underwent 7-10 days of actigraphy monitoring, which provided estimates of 
sleep and circadian functioning, and then neuropsychological testing. Hierarchical 
regression showed that circadian interdaily stability predicted executive function, 
visuospatial function, and psychomotor speed, though not memory, independently of 
sleep. Sleep efficiency independently predicted executive but not other cognitive 
function.   
  vii 
Study 2 examined daily temporal associations between sleep, subjective 
cognition, and mood (anxiety, positive affect) in PD. Twenty participants used a 
smartphone app to engage in 14 days of ecological momentary assessment (EMA) of 
daytime symptoms and subjective sleep quantity and quality. They wore actigraphs for 
objective sleep assessment. The hypothesis was that sleep quality would predict cognition 
and mood. Multilevel modeling indicated that subjective sleep quality was bidirectionally 
associated with mood on a day-to-day basis (i.e., last night’s perceived sleep affected 
today’s mood, which in turn will affect tonight’s sleep). There was also a trend for 
subjective sleep quality to predict the next day’s subjective cognitive function. Objective 
sleep was not associated with any daytime symptoms.  
Study 1 provided the first evidence that circadian rhythm contributes to cognition 
in PD independently of sleep. Study 2 indicated that, on a daily timescale, subjective 
sleep is relevant to mood and possibly cognition in PD, whereas objective sleep is either 
insufficiently sensitive or not relevant. Together these findings support the use of EMA to 
investigate small-timescale interactions among NMS, and present circadian rhythms and 
sleep perception as intervention targets for improving cognition and mood, and ultimately 
for enhancing quality of life in PD.  
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CHAPTER ONE: GENERAL INTRODUCTION 
 
Parkinson’s disease (PD) is a neurodegenerative disease affecting 1-2% of 
American adults over 65 years old, a prevalence projected to double by 2040 (Kowal, 
Dall, Chakrabarti, Storm, & Jain, 2013). In addition to substantial detriment to 
individuals’ quality of life, PD represents a national economic burden of over $20 billion 
per year (Kowal et al., 2013). Given the rising prevalence of PD and its human and 
economic costs, we urgently need to better understand its disease mechanisms in order to 
develop effective and efficient interventions.  
 
PD pathology and non-motor symptoms (NMS) 
PD is diagnosed by the presence of motor disturbance, including akinesia, 
bradykinesia, rigidity, tremor, and disturbance of gait, balance and posture (Massano & 
Bhatia, 2012). Pathogenesis likely begins with the misfolding of alpha-synuclein proteins 
into Lewy neurites and Lewy bodies in the olfactory bulb and enteric nervous system. 
These lesions cause cell death and propagate trans-synaptically, possibly first from the 
enteric nervous system to the lower brainstem, then progressively up through the 
midbrain, forebrain, and neocortex (Del Tredici & Braak, 2016). Braak and colleagues 
(2003) have described six stages of this ascending progression from lower brainstem to 
cortex. Beginning in Stage 3, dopaminergic cell death in the substantia nigra and 
subsequent basal ganglia dysfunction manifest as the cardinal motor symptoms of PD 
(Braak et al., 2003). Prior to this stage, and continuing through the rest of disease 
progression, there is also spreading multisystem cell death in diffuse areas of the brain 
  
2 
that result in non-motor dysfunction (Rodriguez-Oroz et al., 2009). In fact, there is a 
prodromal phase of at least 20 years during which PD pathology manifests solely as non-
motor symptoms (NMS) (Savica, Rocca, & Ahlskog, 2010), ranging from autonomic 
dysfunction to neuropsychiatric disorders such as depression and sleep disturbance 
(Chaudhuri, Odin, Antonini, & Martinez-Martin, 2011; Poewe, 2008). Some prodromal 
NMS strongly predict later PD and PD-related diagnoses. For example, 80% of those 
with rapid eye movement sleep behavior disorder (RBD) go on to develop 
synucleinopathies (Peever, Luppi, & Montplaisir, 2014).   
Prevalence studies have found that NMS affect up to 98.6% of individuals with 
PD (Barone et al., 2009), who typically experience 10-12 symptoms, increasing in 
number with disease duration and severity (Chaudhuri, Healy, & Schapira, 2006). 
Collectively, NMS represent a significant impact on quality of life (Chaudhuri et al., 
2006; Martinez-Martin, 2011), to an even greater extent than motor symptoms (Martinez-
Martin, 2011). Despite their significance, NMS remain under-diagnosed and under-
researched (Chaudhuri et al., 2015; Cronin-Golomb, 2013). Although they likely begin as 
direct manifestations of PD pathology (e.g., cell death in the brainstem resulting in sleep 
disturbance), other factors such as the presence of additional NMS may contribute to their 
exacerbation over time. For example, mood disturbance may exacerbate sleep 
disturbance, and vice versa. In order to develop effective interventions, we need to better 
understand NMS’s etiology, including their interactions with each other.  
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Sleep and circadian rhythm disruption in PD 
One of the most prevalent groups of NMS is sleep and circadian disturbance 
(Duncan et al., 2014), which affects between 60% and 98% of individuals with PD (Adler 
& Thorpy, 2005; Barone et al., 2009) and consistently ranks among the most distressing 
symptoms (Duncan et al., 2014). Sleep disturbance is heterogeneous and multifactorial in 
PD. This broad term includes neurological sleep disorders such as rapid eye movement 
(REM) sleep behavior disorder (RBD) and restless leg syndrome (RLS)/periodic limb 
movement disorder (PLMD); sleep-disordered breathing such as obstructive sleep apnea 
(OSA); psychophysiological sleep problems such as insomnia; as well as circadian and 
daytime disturbances such as excessive daytime sleepiness (EDS) (Chahine, Amara, & 
Videnovic, 2017; Videnovic & Golombek, 2013). It is important to note that, although 
these symptoms likely interact with each other, they are distinct in etiology (Chahine et 
al., 2017). 
Although there has long been interest in sleep disturbance in PD, the bulk of 
research has focused on RBD, a parasomnia characterized by loss of REM sleep paralysis 
and consequent “acting out dreams” (St Louis, Boeve, & Boeve, 2017). RBD is often 
present years or decades before overt motor symptoms, and is a strong predictor of later 
disease onset, with between 35% and 91% of those diagnosed going on to develop PD or 
another disease of synucleinopathy neurodegeneration (St Louis et al., 2017; Peever et 
al., 2014). Among those with diagnosed PD, almost one quarter also have RBD by 
conservative estimates (Zhang, Xu, & Liu, 2017). Although the etiology of RBD is still 
unconfirmed, it likely involves dysfunction in the sublaterodorsal tegmental nucleus, a 
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small region just rostral to the locus coeruleus in the brainstem (Peever et al., 2014). A 
number of studies have characterized RBD’s association with PD disease progression, 
including with greater cognitive decline (Jozwiak et al., 2017). Individuals with PD with 
RBD also show white matter changes (Ansari, Rahmani, Dolatshahi, Pooyan, & Aarabi, 
2017) and greater postmortem density of Lewy pathology compared to those without 
RBD (Postuma et al., 2015). These findings highlight the importance of understanding 
sleep disturbance in PD. RBD, however, is distinct from other common but relatively 
neglected sleep and circadian problems (e.g., insomnia), which may also have important 
roles to play in PD’s pathology and management. 
 
Circadian disruption. 
One relatively neglected symptom of PD is circadian disruption. The circadian 
system is a network of oscillators with approximately 24-hour cycles that dictate a range 
of biological processes, from molecular to behavioral (Granados-Fuentes & Herzog, 
2013). The master endogenous clock is the suprachiasmatic nucleus (SCN) in the brain, 
which receives photic and other environmental inputs (called “Zeitgebers”) to entrain 
itself and peripheral oscillators to the 24-hour environment. Collectively, the circadian 
system influences sleep-wake timing, rest-activity rhythms, cognitive function, endocrine 
function, body temperature, and even gene expression (Granados-Fuentes & Herzog, 
2013). Indeed, it is involved with virtually every biological system in the brain and body. 
We can therefore expect disruption to the circadian system to broadly impact physical 
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and mental health (Videnovic & Golombek, 2013; Videnovic, Lazar, Barker, & Overeem, 
2014; Willison, Kudo, Loh, Kuljis, & Colwell, 2013).  
There is mounting evidence of circadian disruption in PD (Videnovic & Willis, 
2016). For example, PD is associated with flattened and even reversed autonomic 
circadian patterns (Ahsan Ejaz, Sekhon, & Munjal, 2006)—heart rate variability is 
suppressed at night compared to healthy individuals (Mihci, Kardelen, Dora, & Balkan, 
2006; Pursiainen et al., 2002), and both blood pressure and core body temperature 
rhythms lack the normal nighttime “dipping” (Oh et al., 2013; Tsukamoto, Kitano, & 
Kuno, 2013; Zhong et al., 2013). These autonomic circadian abnormalities occur in 
individuals with PD regardless of age, gender, disease severity or motor symptom 
phenotype, reflecting an independent circadian dysfunction rather than a secondary 
consequence of motor symptoms (Oh et al., 2013; Pursiainen et al., 2002; Tsukamoto et 
al., 2013). There is also circadian disruption in the endocrine system, including decreased 
amplitude in the circadian fluctuation of cortisol (Hartmann, 1997), and both decreased 
amplitude and phase advance in fluctuations of blood serum melatonin (Videnovic et al., 
2014). One study also demonstrated flattened diurnal variation in the expression of the 
clock gene Bmal1 (Breen et al., 2014). In terms of behavioral patterns, individuals with 
PD have consistently demonstrated lower rest-activity amplitude than their age-matched 
peers (i.e., increased motor activity at night and decreased activity during the day) (Breen 
et al., 2014; Nass & Nass, 2008; Niwa, Kuriyama, Nakagawa, & Imanishi, 2011; van 
Hilten, 1994; Whitehead, Davies, Playfer, & Turnbull, 2008). Rest-activity patterns are 
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also more fragmented and less predictable than in age-matched adults (Breen et al., 2014; 
Stavitsky & Cronin-Golomb, 2011; Whitehead et al., 2008).  
Understanding circadian disturbance in PD is important because it likely plays a 
role in motor and non-motor symptoms (Videnovic & Golombek, 2013). Circadian 
fluctuations exist in a number of PD’s clinical features, including motor symptoms 
(Bonuccelli et al., 2000), autonomic problems (Arias-Vera, 2003), visual perceptual 
deficits such as contrast sensitivity (Struck, Rodnitzky, & Dobson, 1990), and 
responsiveness to dopaminergic medication (Bonuccelli et al., 2000). Moreover, there is 
significant overlap between NMS and well-documented symptoms of circadian rhythm 
disorders, including sleep-wake problems (Abbott, Soca, & Zee, 2014; Bjorvatn & 
Pallesen, 2009; Buysse, Monk, Carrier, & Begley, 2005; Silva, Wang, Ronda, Wyatt, & 
Duffy, 2010), cognitive impairment (Waterhouse, 2010), and psychiatric symptoms 
(Gerstner & Yin, 2010; Loh et al., 2010; Ruby et al., 2008). There is already preliminary 
evidence associating blunted circadian rhythms in PD with depression (Suzuki et al., 
2007) and cognitive impairment (Whitehead et al., 2008). This area of research is still in 
its infancy, however, and more investigation is needed to characterize circadian 
interactions with NMS (Chahine et al., 2017). In particular, because sleep and circadian 
function are so intimately linked with each other, we need to determine if any circadian 
contributions to NMS are independent from sleep contributions. This would allow us to 
assess circadian function’s usefulness as a treatment target. 
 
Insomnia. 
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 Another relatively neglected sleep problem is insomnia, which is the most 
common sleep complaint in PD (Videnovic & Golombek, 2013). This is a sleep disorder 
characterized by subjective difficulty with falling asleep, staying asleep, waking too 
early, and associated daytime distress and impairment (APA, 2013). The prevalence of 
formally diagnosed insomnia is estimated at 32% in PD, and the prevalence of self-
reported “poor sleep” is 20-80% (Chahine et al., 2017). Objective measures of insomnia 
and sleep quantity and quality in PD are mixed. One polysomnography (PSG) assessment 
found that those with PD have shorter sleep duration and lower sleep efficiency (i.e., 
percent of time in bed spent asleep) than age-matched healthy peers. Among individuals 
with PD, however, there was no significant difference in sleep quantity or quality 
between those who had and those who did not have subjective insomnia (Yong, Fook-
Chong, Pavanni, Lim, & Tan, 2011). At least two other PSG assessment studies found no 
differences in sleep duration or efficiency between PD and control participants (Chung et 
al., 2013; Schroeder et al., 2016). Because insomnia itself is a disorder with multiple 
subtypes and etiologies, and PD is associated with numerous factors that may contribute 
to insomnia (e.g., motor symptoms, other sleep disturbances, nocturia, mood 
disturbance), further investigation is needed to fully understand the causes of insomnia in 
PD (Chahine et al., 2017). 
In addition to being a consequence of other PD symptoms, insomnia may also 
contribute to other NMS, including cognitive impairment (Erro et al., 2012; Neikrug et 
al., 2013), mood disturbance (Chung et al., 2013; Neikrug et al., 2013), and fatigue 
(Neikrug et al., 2013). For example, there is some evidence that sleep efficiency, a well-
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established global marker of insomnia-related sleep quality, is associated with working 
memory and verbal memory (Gunn, Naismith, Bolitho, & Lewis, 2014), and with 
executive function (Stavitsky, Neargarder, Bogdanova, McNamara, & Cronin-Golomb, 
2012). There is also evidence that sleep onset latency (SOL), another commonly used 
insomnia parameter, is associated with executive function in PD (Stavitsky et al., 2012). 
The evidence is mixed, however, with some studies (e.g., Goldman et al., 2013) not 
finding any association between sleep and cognition. There is more convergent evidence 
of sleep’s association with mood disturbance, including both depression (Caap-Ahlgren 
& Dehlin, 2001; Chung et al., 2013; Neikrug et al., 2013; Rutten et al., 2017) and anxiety 
(Pal et al., 2004; Rutten et al., 2017).  
One limitation of the exiting literature is that most studies linking sleep to 
cognition or mood in PD were studies of RBD, with few measuring insomnia or 
insomnia-related sleep variables (e.g., sleep efficiency, duration, onset latency). These 
non-RBD sleep variables may interact with mood and cognition in distinct ways, which 
has implications for assessment and treatment. For example, Chung et al. (2013) found 
that subjective insomnia was associated with depression in PD, but surprisingly, objective 
(i.e., PSG) sleep variables were not. Aitken, Naismith, Terpening, & Lewis (2014) 
replicated and provided a possible explanation for this finding. They found that 
dysfunctional beliefs and attitudes about sleep were associated with mood disturbance, 
whereas objective sleep quantity and quality were not. This suggests that for those with 
PD, insomnia may affect mood through a psychological mechanism rather than a 
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neurological one, therefore warranting its own theoretical framework (and treatment 
design). 
Another major limitation is that most studies used only retrospective self-report 
measures of insomnia symptoms. As Chung et al. (2013) and Aitken et al. (2014) 
demonstrated, subjective and objective measures of sleep quantity and quality can be 
discrepant not only in degree, but also in how they associate with other variables. It is 
especially risky to rely only on self-reported sleep quantity and quality averaged over the 
past weeks/months, because they do not allow assessment of temporal associations, 
thereby increasing the risk of finding spurious associations between sleep and NMS. 
Moreover, with only subjective measures, studies have missed the opportunity to 
characterize meaningful differences between subjective and objective insomnia in PD. 
 Given the prevalence and quality of life costs of insomnia and circadian 
disturbance in PD, we urgently need to better understand them and their potential as 
treatment targets in PD. The existing literature is inadequate in both scope and rigor, 
requiring basic characterization of circadian function’s and insomnia’s potential relations 
with other NMS, use of objective sleep measures, and use of appropriate statistical 
approaches. 
 
Cognitive impairment in PD 
Cognitive impairment is a common and heterogeneous set of symptoms in PD 
(Aarsland et al., 2017) that includes impairment of executive function, attention, 
visuospatial function, and memory (Miller, Neargarder, Risi, & Cronin-Golomb, 2013). 
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Some degree of deficit is present in approximately one third of newly diagnosed 
individuals, increasing in prevalence and severity with disease duration (Litvan et al., 
2011). Ultimately, at least 24-31% of those with PD develop dementia (Aarsland, Zaccai, 
& Brayne, 2005), which is associated with nursing home admission (Aarsland, Larsen, 
Tandberg, & Laake, 2000), caregiver burden (Aarsland et al., 2007), and mortality (Levy 
et al., 2002). Short of dementia, even subtle cognitive deficit early in the disease course 
can have a significant impact on function and quality of life for persons with PD and their 
caregivers (Leroi, McDonald, Pantula, & Harbishettar, 2012; Litvan et al., 2011). Along 
with mood and sleep disturbance, cognitive symptoms rank among the most detrimental 
to quality of life in PD (Duncan et al., 2014).  
The etiology of cognitive impairment in PD is likely multifactorial, including 
contributions from genetic mutations (e.g., duplications and triplications in the a-
synuclein gene), brain pathologies (e.g., cortical Lewy bodies), and neurotransmitter 
dysregulation (e.g., dopaminergic neurodegeneration) (Halliday, Leverenz, Schneider, & 
Adler, 2014). Much research has focused on transmitter-based pharmacological 
interventions for PD with dementia (e.g., levododpa, cholinesterase inhibitors) 
(Svenningsson, Westman, Ballard, & Aarsland, 2012), but medications have not 
demonstrated protective effects for progression from mild cognitive impairment to 
dementia (Aarsland et al., 2017). A small but growing number of studies have found 
cognitive training to be modestly effective for executive functioning, working memory, 
and processing speed (Leung et al., 2015; Walton, Naismith, Lampit, Mowszowski, & 
Lewis, 2017). Another promising intervention is physical exercise, which may promote 
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cerebral perfusion, release of growth factors, or angiogenesis (reviewed in Reynolds, 
Otto, Ellis, & Cronin-Golomb, 2016). These non-pharmacological approaches are 
particularly welcome to individuals with PD, who already have a heavy medication 
burden (Tomlinson et al., 2010).  
Two potential new targets for cognitive intervention in PD are circadian and sleep 
disturbance. It is well known that the circadian system regulates cognition in healthy 
humans (Ly et al., 2016; Waterhouse, 2010), and that its disruption (e.g., shiftwork) is 
associated with impairments to processing speed, memory, and global cognition 
(Marquié, Tucker, Folkard, Gentil, & Ansiau, 2015). Some have suggested that circadian 
disturbance in PD may also contribute to cognitive impairment (Willison et al., 2013), 
though this hypothesis is mainly untested. One study has provided evidence of an 
association between circadian function and cognition in PD (Whitehead et al., 2008), but 
its only measure of cognition was the Mini Mental Status Exam (MMSE). More 
importantly, they did not assess sleep. Given the intimate link between sleep and 
circadian function, we cannot conclude that this circadian association with cognition did 
not in fact reflect a sleep association with cognition in PD.  
 In order to explore circadian function’s potential as a treatment target for 
cognitive impairment in PD, we need to simultaneously assess both sleep and circadian 
function and statistically dissociate their relative contributions to cognition. Ideally, 
multiple domains of cognitive functioning would be assessed. This line of inquiry may 
identify a new treatment target that responds to non-pharmacological interventions 
(Auger et al., 2015). 
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Another promising treatment target for cognitive impairment is sleep disturbance, 
specifically insomnia-related poor sleep quantity and quality. It is well established that 
sleep affects cognitive performance in the general population (Fulda & Schulz, 2001; 
Lim & Dinges, 2010; Olaithe, Bucks, Hillman, & Eastwood, 2017). For example, sleep 
deprivation is associated with impaired attention, learning/memory, and global cognition 
(Lim & Dinges, 2010) and insomnia is associated with impaired working memory (Fulda 
& Schulz, 2001). In PD, preliminary evidence has also emerged to implicate sleep in 
cognitive impairment (Pushpanathan, Loftus, Thomas, Gasson, & Bucks, 2016). 
However, as discussed above, findings on non-RBD sleep quality and cognition in PD are 
scarce and mixed (Goldman et al., 2013; Stavitsky et al., 2012). With the additional 
limitation of few studies objectively measuring sleep, this area of research remains 
inconclusive. 
Nevertheless, the association between sleep quality and cognition has face 
validity and is commonly assumed. In my clinical experience, many individuals with PD 
attribute their cognitive complaints to poor sleep quality, both globally and on an acute 
basis (i.e., last night’s insomnia resulted in today’s cognitive problem). It is unclear, 
however, whether quantitative sleep variables (e.g., sleep duration) in fact play a role in 
cognition (Aitken et al., 2014; Chung et al., 2013). If they do, we would not know on 
what time scale (e.g., days versus months) because all existing studies use sleep data 
aggregated over weeks/months. These questions are important because insomnia has a 
strong psychological component, and an individual’s potential misunderstanding of 
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whether and how sleep affects his/her daytime function may actually exacerbate insomnia 
(Harvey, 2002). 
In order to illuminate the true nature and time scale of any effects sleep quantity 
and quality may have on cognition in PD, we need to study temporal associations 
between sleep and cognitive variables (i.e., day-to-day effects). This approach would also 
help to reveal potential mechanisms of any sleep effects and nominate appropriate 
interventions.  
 
Mood disturbance in PD 
 Besides sleep/circadian disruption and cognitive impairment, a third highly 
prevalent NMS is mood disturbance, which includes anxiety (Broen, Narayen, Kuijf, 
Dissanayaka, & Leentjens, 2016; Reynolds, Barlow, & Cronin-Golomb, 2016), and 
depression (Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008). Meta-analyses on the 
prevalence of mood symptoms in PD have found that nearly one-third of individuals with 
PD have multiple anxiety disorders, with the most common being generalized anxiety 
disorder (14%), social phobia (13.8%), and clinically significant nonspecific anxiety 
(13.3%; Broen et al., 2016); and that 35% have clinically significant depressive 
symptoms (Reijnders et al., 2008). Mood symptoms are highly correlated with lower 
quality of life (Fan, Chang, & Wu, 2016; Gallagher, Lees, & Schrag, 2010; Hanna & 
Cronin-Golomb, 2012; Yamanishi et al., 2013) and greater disability (Witjas et al., 2002), 
sometimes even more so than motor symptoms (Hanna & Cronin-Golomb, 2012; Witjas 
et al., 2002). There is also evidence that anxiety in PD is associated with executive 
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dysfunction (Reynolds, Hanna, Neargarder, & Cronin-Golomb, 2017). Despite their 
importance, mood symptoms are often unrecognized and untreated (Sagna, Gallo, & 
Pontone, 2014).  
 Pharmacological approaches generally have not significantly reduced mood 
symptoms in PD, and there is a lack of large, well-controlled trials (Troeung, Egan, & 
Gasson, 2013). Antidepressants are well tolerated (Peña et al., 2016), but are often not 
effective (Weintraub et al., 2005), and anxiolytics such as benzodiazepines pose risks for 
serious side effects, including ones that would exacerbate existing NMS in PD (e.g., 
autonomic, cognitive, sleep, and psychomotor disturbance) (Reynolds, Otto, et al., 2016). 
Non-pharmacological approaches offer a promising alternative for those with PD, 
including exercise therapy (reviewed in Reynolds et al., 2016), and cognitive behavioral 
therapy for depression (Dobkin, Menza, & Bienfait, 2008; Okai et al., 2013) and anxiety 
(Reynolds, Barlow, & Cronin-Golomb, 2016). Additional trials with larger sample sizes 
and more targeted assessment of mood symptoms are needed to generalize these findings 
(Reynolds, Otto, et al., 2016). 
Another potential approach to treating mood symptoms in PD is to improve sleep. 
As described above, there is substantial evidence that sleep problems are associated with 
mood disturbance, including depression (Borek, Kohn, & Friedman, 2006; Caap-Ahlgren 
& Dehlin, 2001; Neikrug et al., 2013; Rutten et al., 2017; Tandberg, Larsen, & Karlsen, 
1998) and anxiety (Borek et al., 2006; Pal et al., 2004; Rutten et al., 2017). These 
associations may be bidirectional (Rutten et al., 2017), possibly driven by psychological 
factors that link sleep and mood (Aitken et al., 2014). For example, clinical experience 
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shows that many individuals with PD believe that their sleep problems directly and 
immediately affect their mood, and that their mood symptoms, in turn, increase the 
likelihood of having sleep difficulties. Research studies to date have not evaluated this 
clinical intuition, as they have relied on sleep and mood measures that average symptoms 
over long periods. This remains an important clinical and research question: What is the 
direction, degree, and time scale of any bidirectional associations between sleep and 
mood disturbance? The answer may offer new opportunities for improving both mood 
and sleep disturbance in PD. 
 
Potential associations between sleep and circadian disruption, cognitive impairment, 
and mood disturbance 
 Sleep and circadian disruption, cognitive impairment, and mood disturbance are 
three common, debilitating, and complex NMS in PD (Chaudhuri et al., 2011; Videnovic 
& Willis, 2016). They are detrimental to quality of life for individuals with PD (Duncan 
et al., 2014; Martinez-Martin, 2011) and increase caregiver burden (Aarsland et al., 
2007). Each of these three major NMS has a multifactorial and complex etiology, and 
each has the potential to play a role in the others. Understanding the nature, direction, and 
degree of associations between sleep/circadian and daytime functioning can help to 
reveal common underlying mechanisms, which will pave the way for us to develop 
targeted interventions.  
To this end, there are currently several gaps in the existing knowledge. First, there 
are no studies examining independent circadian contributions to daytime functioning in 
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PD. Second, there is scarce and inadequate investigation of whether non-RBD sleep 
variables contribute to daytime function in PD. Third, studies associating sleep quantity 
and quality with daytime symptoms have rarely used objective sleep measures, and even 
more rarely have examined differential actions of subjective versus objective sleep. 
Fourth, these studies have also relied on retrospective measures that averaged sleep and 
daytime symptoms over long periods (i.e., weeks or months), making it impossible to 
examine any small-scale temporal associations between these symptoms. 
 
Specific aims and hypotheses 
This dissertation project aimed to address the above gaps in knowledge through 
two studies: 
Study 1: Circadian rest-activity rhythms and cognitive function in early Parkinson’s 
disease. 
The goal of Study 1 (Chapter Two) was to test the hypothesis that circadian 
function is associated with cognitive function in PD independently of sleep. Using 
objective measures of both circadian rest-activity rhythms and sleep (i.e., actigraphy), I 
sought to determine the relative contributions of each to cognitive functioning. I 
hypothesized that both rest-activity robustness and sleep quality would significantly 
predict performance in multiple cognitive domains (executive function, visuospatial 
function, psychomotor speed, memory). I further hypothesized that circadian function’s 
contribution would be statistically independent from that of sleep, demonstrating that its 
association with cognition is not merely a proxy for sleep’s association with cognition.  
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Study 2. Temporal associations between sleep and daytime functioning in Parkinson’s 
disease: a smartphone-based ecological momentary assessment 
The goal of Study 2 (Chapter Three) was to further probe the nature of sleep’s 
association with cognition, as well as with mood and other daytime function domains. 
Specifically, I aimed to examine possible bidirectional temporal relations between 
nighttime sleep and daytime symptoms, and to do so on a small timescale (i.e., days). To 
achieve this, I used an ecological momentary assessment design that allowed prospective 
repeated measurements of sleep and daytime symptoms over 14 days. In order to 
accurately capture a range of possible sleep factors (e.g., physiological, psychological), I 
measured sleep using both objective and subjective instruments (i.e., actigraphy, sleep 
diary). I hypothesized that sleep quantity and quality would predict next-day cognition, 
mood, and fatigue, and that in turn, mood would predict later sleep quantity and quality. I 
also hypothesized that the smartphone-based daily assessment method would be a 
feasible method for assessing daily symptoms in PD.  
 
  
18 
CHAPTER TWO: CIRCADIAN REST-ACTIVITY RHYTHMS PREDICT 
COGNITIVE FUNCTION IN EARLY PARKINSON’S DISEASE 
INDEPENDENTLY OF SLEEP 
 
Introduction 
Parkinson’s disease (PD) is characterized by motor disturbance as well as a range 
of non-motor symptoms (Chaudhuri et al., 2011). One of the most common and 
debilitating is cognitive impairment, which is present in approximately one third of 
individuals with PD at time of diagnosis, increasing in prevalence and severity with 
disease duration and progressing to dementia for many of these individuals (Litvan et al., 
2011). Even subtle cognitive impairment in early PD can have significant impact on 
quality of life for patients and caregivers. Commonly affected cognitive domains in PD 
without dementia include executive function, attention, visuospatial function, and 
memory, with attention and executive function being prevalent even at earlier stages of 
the disease (Miller et al., 2013). The etiology of cognitive impairment in PD is likely 
multifactorial, and identifying mechanisms may be important for clinical management.  
A candidate mechanism of cognitive impairment in PD is circadian dysfunction. 
In humans, the circadian system is a network of oscillators with approximately 24-hour 
cycles that regulate biological functions at every level throughout the brain and body. 
Disruption to this system can broadly impact physical, emotional and cognitive health 
either directly or via its influence on sleep (Videnovic et al., 2014). While it is well 
established that sleep affects cognitive performance (Walker, 2008). circadian function 
likely also contributes to it independently. For example, rodent studies have demonstrated 
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that disrupted rest-activity rhythm contributes to executive dysfunction and memory 
deficits above and beyond the effects of previous night’s sleep (Wright, Lowry, & 
Lebourgeois, 2012). In humans, multiple studies document the negative cognitive effects 
of shift work (Rouch, Wild, Ansiau, & Marquié, 2005) and jet lag (Cho, 2001), both of 
which feature disrupted circadian rest-activity rhythms. 
Although there is mounting evidence that circadian function is impaired in PD 
(Videnovic & Willis, 2016), there has been no direct assessment of associations between 
circadian and cognitive impairment in this population. A study by Whitehead and 
colleagues (Whitehead et al., 2008) found preliminary evidence for this association with a 
correlation between rest-activity amplitude and Mini-Mental State Exam (MMSE) score. 
The MMSE is a brief dementia screen that does not capture many PD-specific cognitive 
impairments (e.g., executive dysfunction), so more comprehensive and domain-specific 
cognitive assessment is needed. Moreover, it is difficult to conclude a specifically 
circadian role in cognition based only on actigraphic rest-activity data, which reflect not 
only circadian function, but also sleep and sleep-wake timing. Given the known relation 
between sleep and cognitive impairment in PD (Kim et al., 2014; Stavitsky et al., 2012), 
Whitehead et al.’s (Whitehead et al., 2008) finding may not in fact indicate an 
independent circadian association with cognition.  
Despite the possible confluence of circadian and sleep contributions to actigraphy 
data, there are advantages to using actigraphy to characterize behavioral rhythms (e.g., 
non-invasive, inexpensive), and many investigators are using this method to estimate 
possible circadian dysfunction in PD. For example, studies have found that individuals 
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with PD consistently demonstrate lower rest-activity amplitude than their age-matched 
peers (i.e., increased motor activity at night and decreased activity during the day) (Breen 
et al., 2014; Nass & Nass, 2008; Whitehead et al., 2008), as well as rest-activity patterns 
that are more fragmented and less stable (Breen et al., 2014; Stavitsky, Saurman, 
McNamara, & Cronin-Golomb, 2010; Whitehead et al., 2008). These rest-activity 
patterns co-occur with dysregulated melatonin, cortisol and peripheral clock gene 
expression (Breen et al., 2014), which suggests that they include a possible circadian 
component. Actigraphy’s potential for capturing circadian dysfunction suggests that it 
should not be dismissed as a tool for exploring circadian function in PD. Rather, analytic 
techniques should be applied to assess the unique association of circadian with cognitive 
function independently of sleep.  
In the present study, we assessed associations between circadian rest-activity 
rhythms and multi-domain cognitive function in PD, using analytic techniques to reveal 
the unique association of rest-activity rhythms with cognition independent of sleep.  
 
Methods 
Participants. 
Thirty-five individuals with idiopathic PD (mean age = 66.2, SD = 7.9; 13 
women) were recruited from the outpatient Movement Disorders Clinic of the Boston 
Medical Center. They had been assessed as part of a study to test the feasibility of using 
actigraphy to assess sleep quality in PD (Stavitsky et al., 2010) and the relation of night-
time sleep to cognition (Stavitsky & Cronin-Golomb, 2011). Study procedures were 
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approved by the Boston University IRB, and participants provided informed consent. All 
participants were right-handed, except for two left-handed individuals, and were highly 
educated (mean years of education = 16.8, SD = 2.4). None of the participants was 
demented as indexed by MMSE scores above 25 and performance on multiple 
neuropsychological tests. They had no history of substance abuse, head injury, or 
neurologic disorders besides PD. Participants had mild-moderate PD severity per scores 
on the Unified Parkinson’s Disease Rating Scale (UPDRS; mean score = 25.1, SD = 9.4). 
Median Hoehn and Yahr stage was 2 (range = 1-3). Mean disease duration was 8.8 years 
(SD = 5.1). We calculated levodopa equivalent dosages (LED) based on convention 
(Tomlinson et al., 2010). LED was not significantly correlated with sleep, rest-activity, or 
cognitive variables (r’s < .39, p’s > .54).  
 
Measures.  
 Sleep diaries. Participants completed daily sleep diaries during a 7- to 10-day 
period that documented bed and rise times.  
Actigraphy—sleep and circadian rest-activity rhythm. Participants wore 
actigraphs (Actiwatch AW-64; Mini Mitter, Sunriver, OR) continuously over the same 7- 
to 10-day period on the non-dominant wrist. These accelerometers recorded raw activity 
counts in 30-second epochs at the rate of 30 Hz. Using a threshold of 40 activity counts 
within an epoch for “wake” and sleep diaries to corroborate bed and rise times, we 
calculated total sleep time, sleep onset latency, wake after sleep onset (i.e., duration of 
wakefulness during the sleep period), and sleep efficiency (i.e., percentage of time in bed 
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spent asleep). We calculated circadian rest-activity variables using non-parametric 
circadian rhythm analyses (van Someren et al., 1996; Wang et al., 2015): 
Relative amplitude (RA)—ratio of average activity level during the least active 
five hours to the most active 10 hours of each day.  
Interdaily stability (IS)—ratio of activity level variance within each 24-hour 
pattern to the overall variance, essentially a signal-to-noise measure indicating the 
degree of consistency from day to day. A higher value indicates a more stable 
rhythm.   
Intradaily variability (IV)—ratio of the mean squares of the difference between 
consecutive hours and the mean squares around the overall mean, a measure of 
fragmentation. A lower value indicating less fragmented rhythm. 
Neuropsychological tests—cognitive performance. Cognition was assessed using 
standardized neuropsychological tests of executive function and attention, memory, 
psychomotor speed, and visuospatial function, as described in Stavitsky et al., 2011 
(Stavitsky & Cronin-Golomb, 2011). Tests of executive function and attention included 
Verbal Fluency (FAS and Category-Animals), Ruff Figural Fluency, Digit Span 
Backward, Spatial Span Backward, Trail-Making Test B, and the Stroop Color-Word 
Test. Tests of memory included the California Verbal Learning Test-II (CVLT-II), 
including List A total, Short Delay Free Recall, Long Delay Free Recall and Yes/No 
Recognition, and the Brief Visual Memory Test, including Learning, Delayed Recall, and 
Yes/No Recognition (BVMT). Tests of psychomotor speed included Trail Making Test A 
  
23 
and the Purdue Pegboard Test. Tests of visuospatial function included Benton Judgment 
of Line Orientation, Clock Drawing, and the Money Road-Map Test. 
 
Procedures. 
Detailed procedures for recruitment and enrollment are described in Stavitsky et 
al.’s 2010 study (Stavitsky et al., 2010). Briefly, after participants were screened for 
eligibility, they began wearing wrist actigraphs for the following 7-10 days. They were 
instructed to wear their actigraphs continuously and to not change their daily routines or 
their medication regimens. After actigraphic monitoring, participants underwent 
neuropsychological testing in the laboratory.  
 
Data analyses.  
Participants’ scores on neuropsychological tests were converted to z-scores based 
on a matched normal control sample assessed in a previous study (Stavitsky & Cronin-
Golomb, 2011). Z-scores were averaged for executive function, psychomotor speed, 
visuospatial function, and memory to create composite scores of each domain. 
To test the hypothesis that rest-activity rhythm contributes to variance in 
cognitive performance independently of sleep, we performance hierarchical regressions 
with sleep and rest-activity rhythmicity measures as predictors. To preserve statistical 
power and to avoid multicollinearity, we decided a priori that only variables significantly 
correlating with cognitive performance would be used in the hierarchical regression 
analysis: 
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Sleep variables. Both sleep onset latency (SOL) and sleep efficiency were 
significantly correlated with executive function (r’s > .427, p’s < .01), However, we 
decided to use only sleep efficiency as SOL and sleep efficiency are highly correlated 
with each other, and sleep efficiency is the sleep variable conventionally considered to 
reflect overall sleep quality [20]. 
Rest-activity rhythm variables. Among the rest-activity rhythm variables, only IS 
was significantly correlated with cognitive variables (r’s > .396, p’s < .05; Table 1). 
Because both endogenous circadian rhythms and environmentally-imposed behavioral 
schedules (i.e., sleep-wake timing) contribute to IS, we sought to dissociate these two 
elements by calculating both the interdaily stability of rest-activity rhythms (IS) and the 
interdaily stability of sleep-wake schedules based on sleep diary data (ISSW). Of these, IS 
was significantly correlated with cognitive variables, and ISSW was not, r’s < .251, 
p’s > .146. Therefore, we used only IS, and not ISSW, in the hierarchical regression 
analysis. 
These hierarchical regression analyses were performed separately with executive 
function, psychomotor speed, and visuospatial function as the model outcomes. Because 
no sleep or rest-activity variables correlated with memory composite scores, we did not 
perform the regressions with memory as the outcome. For each hierarchical regression, 
the first model (Model 1) included only sleep efficiency, and the second model (Model 2) 
included sleep efficiency and IS. 
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Results 
With executive function as the outcome (Table 2), Model 1 (sleep efficiency only) 
was significant (F[1,33] = 7.059, R2 = .181, p = .012), with sleep efficiency explaining 
18.1% of the variance in performance. The addition of IS in Model 2 (sleep efficiency + 
IS) contributed an additional 14.4% of the variance in executive performance, which was 
significant (F[1,32] = 7.460, R2 = .325, ΔR2 = .144, p = .002). Multicollinearity was not a 
concern, indicated by variance inflation factors (VIF) substantially lower than the 
acceptable threshold of 10 (sleep efficiency, Tolerance = .997, VIF = 1.003; IS, 
Tolerance = .997, VIF = 1.003).  
With visuospatial function as the outcome (Table 3), Model 1 was not significant 
(F[1,33] = 0.301, R2 = .009, p = .591) but Model 2 was (F[1,32] = 3.109, R2 = .163, ΔR2 
= .154, p = .046), with IS contributing a significant portion of the variance (15.4%) to the 
model. Sleep efficiency did not predict visuospatial function (β = .075, t(34) = .457, p 
= .651), but IS did (β = .393, t(34) = 2.385, p = .023).  
Similarly, Model 1 failed to predict psychomotor speed (F[1,33] = .603, p = .443, 
R2 = .019; Table 4), but Model 2 was significant (F[1,32] = 3.741, R2 = .194, ΔR2 = .176, 
p = .035), with IS uniquely explaining 17.6% of the variance in psychomotor 
performance. Sleep efficiency did not predict psychomotor performance (β = .114, t(34) 
= .707, p = .485), but IS did (β = .420, t(34) = 2.602, p = .014).  
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Discussion 
 Among individuals with PD, a more stable circadian rest-activity rhythm was 
associated with better performance on executive, psychomotor, and visuospatial tasks, 
and sleep did not account for these associations. In fact, only rest-activity stability, and 
not sleep efficiency, was significantly associated with psychomotor speed and 
visuospatial function. We further ruled out daily sleep scheduling’s contribution by 
showing that the interdaily stability of sleep-wake timing could not fully explain the 
association between rest-activity rhythm and cognition. Together these findings suggest 
that endogenous circadian function is likely to be the major factor in the observed relation 
between rest-activity rhythm and cognition.  
One possible mechanism by which circadian function contributes to cognition in 
PD is through its regulation of arousal. The circadian system directly regulates arousal 
through projections from the suprachiasmatic nucleus to the brainstem, basal forebrain, 
and hypothalamus (Wright et al., 2012), which in turn affects cognitive performance. 
Further, because cognitive function itself follows diurnal rhythms of behaviors that are 
also modulated by the circadian system, a disrupted circadian system may compound the 
effects of blunted arousal and sleep disturbance through less robust time-of-day signaling. 
Limitations of the present study include small sample size and limited range of 
disease stage (mild to moderate). A larger sample would allow greater statistical power to 
control for age and for disease duration and severity in our assessment of circadian and 
sleep contributions to cognitive performance in PD. In addition, the potential effects of 
daily scheduled behaviors and environmental conditions (e.g., work, exercise, food 
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intake, and light exposure) as well as subjects’ chronotype should be controlled or 
accounted for. 
The present study is the first, to our knowledge, to provide evidence for separate 
contributions from circadian rest-activity rhythm and sleep to cognition in PD. It is also 
one of the first studies to use non-parametric circadian rhythm analyses to characterize 
behavioral rhythms in this population, which allowed us to take advantage of 
prospectively collected 24-hour actigraphy data. Our findings indicate that actigraphy-
derived rest-activity rhythm is not merely a proxy for sleep in its associated with 
cognition in PD, but can serve as an independent predictor. This finding suggests that in 
addition to addressing nighttime sleep, there may be benefit to directly targeting 
behavioral rhythms. For example, a behavioral rhythm intervention that includes timed 
bright light therapy, consistent sleep-wake timing (i.e., creating the opposite effect 
induced by shift-work, jet lag, and napping), meal timing, and other activity scheduling 
may help to strengthen circadian entrainment in order to improve rhythm stability. 
Because the circadian system interacts intimately with multiple motor and non-motor 
systems affected in PD, improving rhythm stability may not only improve cognition 
function but “raise the water for all boats,” such as potentially for mood, autonomic 
function, and sleep. Such a behavioral intervention would be low-risk, easily 
disseminated, and present no issues of drug interaction or side effects—welcome news to 
individuals with PD given their medication burdens.  
Future research should assess circadian function in PD using multiple biomarkers 
(e.g., melatonin secretion, blood pressure) in order to more fully characterize circadian 
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associations with cognition and potentially other non-motor symptoms of PD. Future 
research may also explore the possibility of strengthening circadian robustness by 
stabilizing behavioral rhythms, with the goal of improving non-motor symptoms and 
overall quality of life in individuals with PD.  
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Table 1. Correlations between circadian and cognitive variables.     
 
Memory 
composite 
Executive 
function 
composite 
Psychomotor 
speed composite 
Visuospatial 
function 
composite 
 r p r p r p r p 
Circadian - 
interdaily 
stability 
.176 .311 .401* .017 .424* .011 0.396* 0.018 
Circadian – 
intradaily 
variability 
-.215 .214 -.190 .275 -.239 .167 -0.112 0.522 
Circadian - 
relative 
amplitude 
.160 .360 .206 .235 .147 .401 0.154 0.376 
 
*. Correlation is significant at p < 0.05 level (2-tailed). 
 
Table 2. Summary of hierarchical regression analysis for sleep and circadian 
contributions to executive function. 
 
F R2 R2 
change 
p Beta t  p Collinearity 
(VIF) 
Model 1 7.059 0.181 0.181 0.012 
  
 
 
Sleep efficiency 
    
0.425 2.657  .012 1.000 
Model 2 7.460 0.325 0.144 0.002 
  
 
 
Sleep efficiency 
    
0.405 2.742  .010 1.003 
Interdaily 
stability 
    
0.380 2.573  .015 1.003 
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Table 3. Summary of hierarchical regression analysis for sleep and circadian 
contributions to visuospatial function. 
 
F R2 R2 
change 
p Beta t  p Collinearity 
(VIF) 
Model 1 .301 0.009 0.009 0.591 
  
 
 
Sleep efficiency 
    
0.096 .544  .591  1.000 
Model 2 3.109 0.163 0.154 0.046 
  
 
 
Sleep efficiency 
    
0.075 .457  .651 1.003 
Interdaily 
stability 
    
0.393 2.385  .023 1.003 
 
Table 4. Summary of hierarchical regression analysis for sleep and circadian 
contributions to psychomotor speed. 
 
 
F R2 R2 
change 
p Beta t  p Collinearity 
(VIF) 
Model 1 .603 0.019 0.019 0.443 
  
 
 
Sleep efficiency 
    
0.136 .777  .443 1.000 
Model 2 3.741 0.194 0.176 0.035 
  
 
 
Sleep efficiency 
    
0.114 .707  .485 1.003 
Interdaily 
stability 
    
0.420 2.602  .014 1.003 
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CHAPTER THREE: TEMPORAL ASSOCIATIONS BETWEEN SLEEP AND 
DAYTIME FUNCTIONING IN PARKINSON’S DISEASE: A SMARTPHONE-
BASED ECOLOGICAL MOMENTARY ASSESSMENT 
 
Introduction 
 Parkinson’s disease (PD) is associated with non-motor symptoms (NMS), 
including sleep-wake dysregulation, cognitive impairment, and mood disturbance 
(Chaudhuri, Odin, Antonini, & Martinez-Martin, 2011; Poewe, 2008). These NMS affect 
almost all individuals with PD (Barone et al., 2009) and have an even greater impact on 
quality of life than do motor symptoms (Martinez-Martin, 2011), but remain under-
diagnosed and under-treated (Chaudhuri et al., 2015).  
One of the most prevalent and distressing NMS is sleep disturbance, which affects 
60-98% of individuals with PD and ranks among the strongest contributors to quality of 
life (Duncan et al., 2014). Sleep disturbance, moreover, is thought to contribute to other 
functional domains such as cognition and mood (Neikrug et al., 2013; Pushpanathan et 
al., 2016), although the evidence is mixed (Goldman, Stebbins, Leung, Tilley, & Goetz, 
2014; Naismith, Terpening, Shine, & Lewis, 2011). A recent meta-analysis found that 
sleep affects global cognition, long-term recall, and executive function in PD 
(Pushpanathan et al., 2016), and there is ample evidence that sleep problems are 
associated with mood disturbance, including depression (Borek, Kohn, & Friedman, 
2006; Caap-Ahlgren & Dehlin, 2001; Neikrug et al., 2013; Rutten et al., 2017; Tandberg, 
Larsen, & Karlsen, 1998) and anxiety (Borek et al., 2006; Pal et al., 2004; Rutten et al., 
2017).  
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Existing studies, however, have overrepresented rapid eye movement sleep 
behavior disorder (RBD) (Pushpanathan et al., 2016), making it difficult to tell if 
common sleep complaints such as insomnia also had an effect on cognition or mood in 
PD. Different types of sleep disturbance could affect or be affected by cognition and 
mood in different ways (Borek et al., 2006; Rutten et al., 2017), which has implications 
for assessment and treatment. For example, Aitken and colleagues found in individuals 
with PD and insomnia that dysfunctional beliefs and attitudes about sleep were associated 
with mood disturbance, whereas objective measures of sleep quantity and quality were 
not (Aitken, Naismith, Terpening, & Lewis, 2014). These findings suggest that insomnia, 
a disorder of distorted sleep perceptions and cognitions, may affect mood through 
psychological processes that warrant a different treatment from that for other sleep 
disorders.  
In addition to neglecting non-RBD sleep, most studies have only used self-
reported measures of sleep. Perception of sleep quantity and quality is often discrepant 
from objectively-measured sleep (Harvey & Tang, 2012; Lauderdale, Knutson, Yan, Liu, 
& Rathouz, 2008). Retrospective questionnaires asking about aggregated sleep quality 
over the course of past weeks/months (e.g., Pittsburg Sleep Quality Index) may be 
particularly prone to recall bias. Several studies on sleep and cognition in PD have used 
polysomnography but again, these focused on RBD and did not assess other aspects of 
sleep quantity or quality (Bugalho, Silva, & Neto, 2011; Gagnon et al., 2009; Lavault et 
al., 2010; Sixel-Doring, Trautmann, Mollenhauer, & Trenkwalder, 2011). Some studies 
have done so using actigraphy (Gunn, Naismith, Bolitho, & Lewis, 2014; Stavitsky & 
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Cronin-Golomb, 2011), which Stavitsky and colleagues validated as an alternative for 
objectively measuring sleep in PD (Stavitsky & Cronin-Golomb, 2011). These studies, 
like those using retrospective questionnaires, could not assess temporal associations 
between sleep and daytime symptoms on a meaningfully small timescale (i.e., days). In 
fact, almost all studies on this topic are cross-sectional, making it difficult to assess the 
validity and direction of the reported relations.  
We aimed to address these gaps in knowledge by focusing on non-RBD variables 
of sleep quantity and quality, using both objective and subjective sleep measures, and 
using ecological momentary assessment (EMA) to investigate day-to-day interactions 
between sleep, cognition, and mood. EMA is an intensive longitudinal method for 
collecting data, wherein individuals repeatedly report their experience over a brief period. 
This maximizes ecological validity by assessing individuals in their natural 
environments, and minimizes recall bias by asking about experiences occurring in the 
current moment. It can be administered concurrently with objective sleep monitoring 
(i.e., actigraphy), allowing us to investigate temporal associations between variables. It is 
also more sensitive to change in mood symptoms on a short time scale than other 
methods (Moore, Depp, Wetherell, & Lenze, 2016). A systematic review of EMA in 
aging research found it to be a feasible and useful method for monitoring daily 
functioning (Cain, Depp, & Jeste, 2009). Although some studies have used mobile 
technologies to assess or treat motor symptoms in PD (Lakshminarayana et al., 2017; 
Pfeiffer et al., 2016), none has used EMA to assess NMS. Hence, our final aim was to test 
the feasibility of using smartphone-based EMA to assess NMS. 
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Methods 
Participants. 
Participants were 20 community-dwelling individuals with idiopathic PD without 
dementia (7 women; mean age = 66.5 years, SD = 9.3; 16 right-handed, 3 left-handed, 1 
ambidextrous). PD severity was mild-moderate as determined using the Unified 
Parkinson’s Disease Rating Scale (UPDRS) (mean = 35.2, SD =14.9). Median Hoehn and 
Yahr stage was 2 (Hoehn & Yahr, 1967), with one participant being in stage 4 and the 
rest in stages 1 to 3. Mean disease duration was 6.0 years. All participants had Mini-
Mental State Examination (MMSE) scores above 25 (mean = 28, SD = 1.4). They had no 
history of substance abuse, traumatic brain injury, significant eye disease, intracranial 
surgery, or neurologic, psychiatric, or serious chronic medical disorders besides PD. All 
had access to a smartphone or tablet with wifi capabilities.  
 
Measures. 
EMA assessments. 
Objective sleep. Actigraphs (ActiGraph GT9X Link; Actigraph, Pensacola, FL), 
wrist-worn accelerometers that capture moment-to-moment activity levels, were used to 
estimate sleep and wakefulness. Participants wore actigraphs continuously for 14-15 
days. They were instructed to engage in their normal routines. 
Subjective sleep. Each morning, participants completed the Consensus Sleep 
Diary – Core (Carney et al., 2012; Appendix A), a 10-item self-report of the previous 
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night’s duration of time in bed (TiB), total sleep time (TST), sleep onset latency (SOL), 
number of awakenings (NWK), total wake after sleep onset (WASO), and overall 
subjective sleep quality (SQ). From these variables, we calculated subjective sleep 
efficiency ([TST – SOL – WASO]/TiB). SQ was rated on a 5-point Likert-like scale from 
“very poor” to “very good.”  
Daytime symptoms and functioning. Twice daily, participants completed a 
modified Neuro-QOL (Nowinski et al., 2016; Appendix B) to rate their mood (anxiety 
and positive affect), subjective cognitive functioning, fatigue, and social functioning. 
Items probed participants’ degree of concern/satisfaction on 5-point Likert-like scales. 
Items were originally designed to assess functioning in the past week. We modified 
wording to capture in-the-moment functioning, rather than retrospective, aggregated 
functioning. For example, instead of presenting, “In the past week, I felt nervous,” we 
presented, “Right now, I’m feeling nervous.”  
 
Procedure.  
All procedures were approved by the Boston University Institutional Review 
Board. Participants were recruited from the Great Boston area through the Fox Trial 
Finder and from former participants in Boston University studies who agreed to be 
contacted for future studies.  
 Baseline in-laboratory assessment and training. Participants provided informed 
consent. They underwent UPDRS and MMSE and learned to wear the actigraph monitor 
and perform EMA procedures.  
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 Ecological momentary assessment (EMA). During the training session, research 
staff helped participants to download the EMA app (SymTrend; Cambridge, MA) onto 
their smartphones/tablets. Beginning on the morning after training, EMA assessments 
were administered for 14-15 consecutive days. Participants logged onto their SymTrend 
account daily and submitted their responses to questionnaire items. Electronic responses 
were kept in encrypted, HIPAA-approved Cloud storage hosted by SymTrend, accessible 
only to study staff.  
Each day, participants received automated text messages from SymTrend 
reminding them to complete each of their three daily assessments (one sleep diary, two 
daytime symptom questionnaires). The timing of the reminder messages was decided at 
the training session based on participant preference, and generally fell within 1 hour of 
habitual rise time, lunchtime and bedtime. If they could not complete the assessment at 
the time of the reminder, participants were instructed to complete them as soon as 
possible within the same day. To encourage adherence with EMA completion and 
actigraph return, we informed participants of incentives including a modest completion 
bonus.  
 Debriefing. After receipt of a participant’s actigraph, we generated a basic sleep 
report, which included nightly SOL, TST, SE, WASO, NWK, as well as activity levels 
during the day. Accompanying this report, we provided written explanations of what each 
variable represents, as well as a strong disclaimer that this report did not serve diagnostic 
purposes, should not replace prescribed diagnostic testing, and was not generated with 
  
37 
input from a medical doctor. Participants were encouraged to submit questions regarding 
their reports.  
 
Data analysis.  
Missing data. Overall, 6.3% of EMA and sleep diary data points were missing as 
a result of participants missing the time window for an assessment or neglecting to 
complete it. The amount of missing data was not predicted by age (p = .21), education (p 
= .34), disease duration (p = .73), or disease severity (p = .54).  
Temporal associations between sleep and daytime symptoms. Because each 
participant provided multiple data points, we could not assume independence across 
measurements. Therefore, we constructed multi-level models (MLM), with sleep and 
daily symptoms nested within individuals. Level 2 equations were specified to model 
between-person variability (e.g., disease severity) and Level 1 equations were specified to 
model within-person variability (e.g., daily sleep quality). We specified full maximum 
likelihood estimation, and an autoregressive (AR[1]) repeated covariance type, which 
controls for auto-correlations of residuals (Rovine & Walls, 2012).  
To assess possible acute and cumulative effects of sleep on daytime symptoms, 
we computed lagged variables for up to three days for each sleep variable. For example, 
sleep duration was represented by last night’s sleep duration, the average of the past two 
nights’ sleep durations, and the average of the past three nights’ sleep durations. To 
account for multiple analyses, alpha was set at a conservative .01.  
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Results 
Adherence and Feasibility. 
Over 14-15 days, each participant had 42-45 assessments. Overall, they were 
highly adherent. Average completion rate was 94.1% for sleep diaries and 91.2% for 
daytime symptom questionnaires (92.1% overall). Of 20 participants, 18 completed at 
least 85% of QOL questionnaires, and 19 completed at least 85% of sleep diaries.  
Sleep Quality. 
Participants demonstrated generally good sleep quantity and quality (Table 5). As 
estimated by actigraphy, participants slept 6.5 hours per night on average (SD = 1.3 
hours). They had short SOL (mean = 7.6 min, SD = 5.3 min), but long WASO (mean = 
69.1 min, SD = 49.8 min). They demonstrated good sleep efficiency, spending on average 
83.8% (SD = 10.1%) of time in bed asleep. Participants rated their sleep quality to be 
high, averaging 3.7 out of 5 (SD = 0.5).  
 
Daily Symptom Ratings. 
Daytime symptoms (anxiety, positive affect, cognition, fatigue, and social 
functioning) were scored from 1 to 5, where higher scores represented greater 
endorsement (e.g., greater anxiety, greater positive affect). Participants reported low 
anxiety (mean = 1.3, SD = 0.4), low subjective cognitive impairment (mean = 1.2, SD = 
0.9), low-moderate fatigue (mean = 1.8, SD = 0.6), moderately high positive affect (mean 
= 4.3, SD = 1.9), and moderately high social functioning (mean = 4.3, SD = 0.4).  
Sleep effects on cognition, mood, fatigue, and social function. 
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To evaluate whether subjective and objective sleep predicted later daytime 
symptoms, separate MLMs were constructed with each objective and subjective sleep 
variable (sleep efficiency, TST, WASO, NWK, SOL, SQ) as level 1 (within-person) 
fixed effects. Each model also contained the lagged predictor variables (e.g., mean SQ for 
the past two nights, mean SQ for the past three nights) as fixed effects. To evaluate the 
contribution of disease severity to the model, it was included as a level 2 (between-
person) fixed effect.  
Level 1 (within-person) results showed that no objective (i.e., actigraphy) sleep 
variables, whether acute (i.e., night-before) or cumulative (i.e., mean of past two or three 
nights), were associated with later daytime symptoms (p’s>.112). Of the subjective 
(diary) sleep variables, SQ significantly predicted next-day anxiety (B = -.75, SE = .25, p 
= .003), where each one-level decrease in SQ (out of five) predicted 0.75 points increase 
in anxiety (Table 6). There was also a trend for SQ predicting next-day cognitive 
symptoms (B = -.64, SE = .30, p = .036), and a trend for subjective NWK predicting 
next-day anxiety (B = .231, SE = .107, p = .031). Other subjective sleep variables (TST, 
SOL, WASO, sleep efficiency) did not predict daytime symptoms (p’s>.106; Table 7). 
Level 2 results revealed a trend for disease severity to predict fatigue (B = 0.14, SE = .06, 
p = .041), but it did not predict other daytime symptoms (p’s>.139). 
 
Mood effects on sleep. 
To evaluate whether mood predicted later sleep, MLMs were constructed with 
anxiety and positive affect as level 1 fixed effects. Disease severity was again included as 
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a level 2 effect. Positive affect significantly predicted later SQ (B = 0.03, SE = .01, p = 
.003), and there was a trend for anxiety to predict SQ (B = -0.06, SE = .03, p = .021). 
There was also a trend for positive affect to predict subjective TST (B = -0.17, SE = .77, 
p = .029). Mood variables did not predict any other subjective (p’s>.188) or objective 
sleep parameters (p’s>.107). Disease severity was not significantly associated with any 
sleep outcomes (p’s>.037). 
In sum, subjective sleep quality significantly predicted next-day anxiety, and there 
was a trend for it to predict next-day subjective cognitive function. There was also a trend 
for subjective number of awakenings to predict anxiety. Objectively-measured sleep did 
not predict any daytime symptoms, and anxiety and positive affect did not predict 
objective sleep. Positive affect predicted subjective sleep quality ratings, and there was a 
trend for it to predict subjective sleep duration. Disease severity did not account for these 
associations between sleep and daytime symptoms. 
 
Discussion 
 We used ecological momentary assessment (EMA) and actigraphy to assess daily 
temporal associations between sleep (subjective and objective) and daytime functioning 
in individuals with PD. Although daily cognitive and affective functioning did not 
fluctuate as a function of the previous night’s (or several nights’) sleep, participants 
nevertheless perceived such an effect. Further, their mood predicted how they would later 
perceive sleep, but did not predict the objective quantity or quality of sleep. It appears 
that perception of sleep quality had a bidirectional association with mood (and perhaps 
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also affected subjective cognition), whereas the objective quantity/quality of sleep neither 
affected nor was affected by these daytime symptoms. 
 This was the first study to use EMA of sleep and daytime symptoms in PD. We 
demonstrated the feasibility of using smartphone-based EMA to assess subjective sleep, 
cognition, affect, fatigue, and social function. Our findings extend and clarify previous 
observations of sleep’s associations with cognition and mood. Previous studies either 
focused exclusively on RBD (Gagnon et al., 2009; Lavault et al., 2010; Sixel-Doring et 
al., 2011), or used retrospective and aggregated measures of sleep and daytime symptoms 
(Goldman et al., 2013; Gunn et al., 2014; Naismith et al., 2011; Rutten et al., 2017; 
Stavitsky & Cronin-Golomb, 2011), which is subject to recall bias and does not allow for 
assessment of temporal associations. Using EMA, we were able to track day-to-day 
associations between sleep and daytime symptoms, and to discover that these variables 
did not vary together on a meaningfully small timescale. Moreover, previous findings 
usually relied on self-reported sleep, which is often discrepant from objectively measured 
sleep (Harvey & Tang, 2012). By simultaneously measuring sleep subjectively and 
objectively, we were able to dissociate their separate associations with daytime function.  
There are several possible explanations for why subjective and objective sleep 
differentially associated with daytime function. First, subjective sleep quality was 
possibly capturing something other than the sleep variables we assessed (sleep latency, 
duration, and efficiency; duration and number of awakenings), such as percentage of time 
spent in each sleep stage. Second, the perception of sleep quality was directly affecting 
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daytime functioning. Third, participants were retrospectively rating their sleep quality 
based on how they felt at the time of EMA data collection (i.e., in the daytime).  
The second and third possibilities, if valid, suggest that modifiable psychological 
targets may exist for improving daytime function. For example, misattribution of daytime 
symptoms to sleep problems may directly increase anxiety or cause misperception of 
sleep quality (e.g., “if I feel poorly now, it must be because I didn’t sleep well last 
night”). In turn, high anxiety may lead to hypervigilance of nighttime awakenings, which 
are then perceived as poor sleep. This bidirectional relation may thus be driven by 
dysfunctional beliefs about sleep and misperception of sleep, which are hallmark 
mechanisms underlying psychophysiological insomnia (Harvey, 2002; Hiller, Johnston, 
Dohnt, Lovato, & Gradisar, 2015). Fortunately, these mechanisms respond well to 
cognitive and behavioral therapy for insomnia (CBT-I) (Eidelman et al., 2016). One 
study has reported that this brief, non-pharmacological intervention is efficacious for 
treating insomnia in PD, but CBT-I was combined with light therapy in this trial 
(Romenets et al., 2013). Future trials are needed to assess CBT-I’s independent 
effectiveness, and to assess related improvements in mood and cognitive function.  
 An unexpected finding was that no sleep variables, subjective or objective, 
predicted next-day fatigue. Previous evidence for the association between sleep and 
fatigue in PD is surprisingly sparse and mixed (Chung et al., 2013; Goldman et al., 2014; 
Havlikova et al., 2008; Neikrug et al., 2013), given the intuitive association between 
these symptoms. Studies on sleep and excessive daytime sleepiness (EDS), a symptom 
that is related to but distinct from fatigue, have also yielded mixed results in PD (Arnulf 
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et al., 2002; Rye, Bliwise, Dihenia, & Gurecki, 2000; Stavitsky, Saurman, McNamara, & 
Cronin-Golomb, 2010). We found no association between sleep and fatigue when 
prospectively measuring these two variables on a small timescale. Future studies are 
needed to simultaneously assess EDS on a small timescale, because clinical experience 
shows that individuals often attribute fatigue and EDS to recent poor sleep quality. 
Educating those with PD about the lack of day-to-day association between sleep and 
daytime symptoms may help to decrease dysfunctional beliefs about sleep, thereby 
decreasing anxiety about sleep and improving overall function.  
 There are several limitations to the present study. First, to minimize participant 
burden, we relied on self-report to measure daily cognitive functioning. Future 
investigations should develop feasible methods for objectively assessing cognition using 
EMA. Second, we did not use polysomnography. Actigraphy provides an estimate of 
sleep based on movement, and there is concern that actigraphs may have low sensitivity 
to wakefulness (Sadeh, 2011). Several studies have successfully used actigraphy to 
measure sleep in PD, however, including in conjunction with assessment of subjective 
perception of sleep (Aitken et al., 2014; Gunn et al., 2014; Stavitsky & Cronin-Golomb, 
2011). Third, the modified NeuroQOL we used to assess daytime function did not 
specifically probe depression or excessive daytime sleepiness. Although it did assess 
anxiety and positive affect, these constructs are orthogonal to depression and may not 
capture affective experiences that are common in PD. Similarly, although we assessed 
fatigue, daytime sleepiness is a separate and common symptom, and one that may be 
independent from nighttime sleep in its association with cognitive function (Goldman et 
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al., 2013). Lastly, our participants were restricted in range of disease severity, daytime 
functioning, and degree of sleep complaints, limiting the generalizability of our findings. 
It may be that those with objectively worse sleep (e.g., clinically significant insomnia) 
experience a different temporal association between sleep and daytime functioning.  
Our findings suggest that for individuals with mild-moderate PD, the perception 
of sleep quality affects, and is affected by, mood symptoms on a daily basis. This focus 
on perception highlights the potential for psychological interventions to address this 
common and distressing NMS. We also demonstrated the feasibility of using 
smartphones to assess NMS. This promising method will allow PD researchers to gather 
longitudinal data in an ecologically valid way, and to explore temporal associations 
between symptoms and interventions. Finally, we found a robust pattern of effects even 
in individuals with PD whose sleep was objectively and subjectively good. This approach 
may be even more sensitive to interactions between symptoms for individuals with PD 
whose sleep quality is poor. 
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Table 5. Mean objective (actigraphy) and subjective (diary) sleep during EMA. 
 
 Objective (actigraph) Subjective (diary) 
TST (min) 392.3 427.5 
SOL (min) 7.6 16.6 
WASO (min) 69.1 21.2 
Sleep efficiency (%) 83.9 91.4 
NWK 12.1 1.8 
SQ (1-5)a N/A 3.72 
 
Note. TST = total sleep time; SOL = sleep onset latency; WASO = wake after sleep 
onset; NWK = number of awakenings; SQ = subjective quality.  
a Higher SQ rating represents better subjective quality of sleep. 
 
Table 6. Results of multilevel modeling analysis predicting anxiety and cognition 
from subjective sleep quality for the past 3 nights. 
Outcome = Anxiety B SE df t p 
Level 2      
Disease severity 0.02 0.04 19.91 0.46 0.649 
Level 1      
SQ_t-1 -0.75 0.25 217.92 -2.99 0.003 
SQ_t-2 0.24 0.50 218.02 0.49 0.623 
SQ_t-3 0.82 0.53 226.55 1.56 0.121 
Outcome = Cognition B SE df t p 
Level 2      
Disease severity 0.09 0.06 20.05 1.41 0.174 
Level 1      
SQ_t-1 -0.64 0.30 220.03 -2.11 0.036 
SQ_t-2 0.62 0.60 220.07 1.04 0.298 
SQ_t-3 -0.17 0.64 225.33 -0.27 0.789 
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Table 7. Results of separate multilevel modeling analyses predicting anxiety and 
cognition from sleep variables. 
 Subjective (diary) Objective (actigraphy) 
Outcome = Anxiety 
 B SE df t p B SE df t p 
TST 0.00 0.00 277.72 -0.52 0.60 0.00 0.00 261.30 -0.29 0.77 
SOL 0.01 0.01 253.44 1.09 0.28 0.01 0.02 267.77 0.31 0.76 
WASO 0.00 0.01 256.19 0.39 0.70 0.00 0.00 246.06 -0.66 0.51 
SE -1.52 2.31 276.69 -0.66 0.51 0.01 0.02 240.53 0.33 0.74 
NWK 0.23 0.11 250.38 2.16 0.03 -0.02 0.03 273.40 -0.65 0.52 
SQ -0.75 0.25 217.92 -2.99 <0.01      
Outcome = Cognition 
TST 0.00 0.00 275.15 -0.02 0.98 0.00 0.00 279.84 -0.26 0.79 
SOL -4.72 2.91 276.20 -1.62 0.11 -0.03 0.03 277.31 -1.21 0.23 
WASO 0.01 0.01 245.74 0.92 0.36 0.02 0.02 261.90 1.07 0.29 
SE 0.01 0.01 247.99 0.78 0.43 0.01 0.01 274.83 1.13 0.26 
NWK -0.12 0.13 243.40 -0.92 0.36 0.07 0.04 271.77 1.60 0.11 
SQ -0.64 0.30 220.03 -2.11 0.04      
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Appendix A. Consensus Sleep Diary – Core questionnaire items. 
 
 
"What time did you get into bed last night?" 
 
"What time did you try to go to sleep?" 
 
"How long did it take you to fall asleep?" 
 
"How many times did you wake up, not counting your final awakening?" 
 
"In total how long did these awakenings last?" 
 
"What time was your final awakening?" 
 
"What time did you get out of bed for the day?" 
 
"How would you rate the quality of your sleep?" 
{Very poor, Poor, Fair, Good, Very good} 
 
"Other comments [optional]" 
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Appendix B. Modified NeuroQOL questionnaire items. 
 
Anxiety 
"Right now, how uneasy do you feel?" 
{Not at all uneasy, A little uneasy, Somewhat uneasy, Quite uneasy, Extremely uneasy} 
"Right now, how nervous do you feel?" 
{Not at all nervous, A little nervous, Somewhat nervous, Quite nervous, Extremely 
nervous} 
"Right now, how worried are you?" 
{Not at all worried, A little worried, Somewhat worried, Quite worried, Extremely 
worried} 
“Right now, my worries are overwhelming me" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, how tense do you feel?" 
{Not at all tense, A little tense, Somewhat tense, Quite tense, Extremely tense} 
"Right now, I am having difficulty calming down" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
“Right now, are you having any feelings of panic?" 
{No panic at all, A little bit of panic, Some panic, Quite a bit of panic, Extreme panic} 
 
Positive affect 
"Right now, I have a sense of well-being" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I feel hopeful" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, my life is satisfying" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
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"Right now, I feel that my life has purpose." 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I feel that my life has meaning." 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I feel cheerful" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I feel that my life is worth living" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I have a sense of balance in my life" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, many areas of my life are interesting to me" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
 
Cognition 
"Right now, my thinking is slow" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I have to work really hard to pay attention or I would make a mistake" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I have trouble concentrating" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Today, how much difficulty did you have with reading and following complex 
instructions?" 
{No difficulty at all, A little difficulty, Some difficulty, Quite a bit of difficulty, Extreme 
difficulty} 
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"Today, how much difficulty did you have with planning for and keeping appointments 
that are not part of your daily routine?" 
{No difficulty at all, A little difficulty, Some difficulty, Quite a bit of difficulty, Extreme 
difficulty} 
"Today, how much difficulty did you having with managing your time to do most of your 
daily activities?" 
{No difficulty at all, A little difficulty, Some difficulty, Quite a bit of difficulty, Extreme 
difficulty} 
"Today, how much difficulty did you having with learning new tasks or instructions?" 
{No difficulty at all, A little difficulty, Some difficulty, Quite a bit of difficulty, Extreme 
difficulty} 
 
Fatigue 
"Right now, I feel exhausted" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, how energetic do you feel?" 
{Not energetic at all, A little bit energetic, Somewhat energetic, Quite energetic, 
Extremely energetic} 
"Right now, how fatigued do you feel?" 
{Not at all fatigued, A little fatigued, Somewhat fatigued, Quite fatigued, Extremely 
fatigued} 
"Right now, I feel too tired to do household chores" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
“Right now, I feel energetic enough to leave the house"" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, I am frustrated by being too tired to do the things I want to do" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Right now, how tired do you feel?" 
{Not at all tired, A little tired, Somewhat tired, Quite tired, Extremely tired} 
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Social Functioning 
"Today, I could keep up with my family responsibilities" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
“Today, I was able to keep up with my social commitments" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Today, I was able to participate in leisure activities" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Today, I was able to perform my daily routines" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
"Today, I was able to keep up with my work responsibilities (including work at home)" 
{Completely disagree, Somewhat disagree, Neither disagree nor agree, Somewhat agree, 
Completely agree} 
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CHAPTER FOUR: GENERAL DISCUSSION 
 
 The non-motor symptoms (NMS) of PD, such as sleep and circadian disruption, 
cognitive impairment, and mood disturbance, have a tremendous impact on quality of life 
(Chaudhuri et al., 2011; Cronin-Golomb, 2013; Videnovic & Willis, 2016). In order to 
develop effective interventions for NMS, we must better understand their mechanisms. 
This dissertation project contributed to this effort by investigating the independent role of 
circadian function in cognitive performance (Study 1) and characterizing temporal 
associations sleep, mood, and cognition on a small timescale (Study 2). 
 
Circadian function and cognitive performance in PD 
 Study 1 examined whether rest-activity circadian function is associated with 
cognitive performance in PD. I predicted that circadian function would not only predict 
cognitive performance, but that it would do so independently of sleep. There was a sound 
theoretical basis for this hypothesis, given circadian function’s known role in regulation 
cognition in the general population (Ly et al., 2016; Waterhouse, 2010), but it had been 
virtually untested in previous studies. The only preliminary evidence for a correlation 
between circadian and cognitive function in PD relied on a brief cognitive screening 
measure (i.e., MMSE), and did not account for possible sleep effects (Whitehead et al., 
2008).  
I used actigraphy to measure sleep quantity, sleep quality, and circadian 
robustness in 35 individuals with PD over the course of 7-10 days. Non-parametric 
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circadian rhythm analysis (NPCRA) allowed me to characterize circadian variables such 
as interdaily stability, a marker of day-to-day consistency in gross behavioral patterns. I 
assessed cognitive performance using standard neuropsychological testing of executive 
function, visuospatial function, psychomotor speed, and memory. Circadian interdaily 
stability significantly predicted executive function independently from sleep, and it 
predicted visuospatial function and psychomotor speed whereas sleep did not. 
One strength of this study was the use of objective measures for circadian, sleep, 
and cognitive function. Another strength was statistically probing the relative and 
independent contributions of circadian versus sleep variables. This approach allowed me 
to demonstrate for the first time that circadian function uniquely contributes to cognition, 
and is not merely a proxy for sleep contributions to cognition in PD.  
Questions still remain regarding the mechanisms underlying circadian 
abnormalities in PD. Whitehead et al. (2008) speculated that increased nighttime activity 
and daytime napping, in particular, are likely due to loss of hypocretin-producing neurons 
in the hypothalamus. Consistent with this idea, a postmortem study found severely 
reduced hypocretin neurons and ventricular cerebrospinal fluid hypocretin levels in PD 
compared to healthy brains (Fronczek et al., 2007). Another study reported normal 
cerebral spinal fluid (CSF) hypocretin-1 levels in a case study of three individuals with 
PD (Overeem et al., 2002), but had specifically recruited cases with dopamine therapy-
induced excessive daytime sleepiness, so these individuals’ circadian disruptions may 
represent only one subtype among those with PD. Another possible explanation for 
circadian abnormalities in PD is the loss of neurons in the suprachiasmatic nucleus 
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(SCN), the “central clock,” which has been well documented in individuals with 
dementia (reviewed in Slats, Claassen, Verbeek, & Overeem, 2013), though there is no 
report of SCN integrity in human PD specifically. Circadian disruption in PD, therefore, 
warrants further investigation on several levels. We need better understanding of its 
neural basis, as well as more evidence for its utility as an independent biomarker and 
potential treatment target. 
 
Temporal associations between sleep and other NMS 
Study 2 focused on sleep’s associations with other NMS. It investigated whether 
sleep quantity and quality predicted, or were predicted by, daytime mood, cognition, and 
fatigue on a small timescale. Ample empirical evidence, as well as clinical intuition, has 
pointed to bidirectional associations between sleep and these daytime functions (Chung et 
al., 2013; Neikrug et al., 2013; Pushpanathan et al., 2016). A close examination of 
evidence, however, suggests that there are meaningful gaps in knowledge. First, while 
there is robust evidence for rapid eye movement behavior disorder’s (RBD’s) association 
with cognition, less is known about general sleep parameters and insomnia symptoms, 
even though insomnia is more common than RBD (Chaudhuri et al., 2011). Second, 
studies have largely relied on sleep measures that are subjective, retrospective, and based 
on cumulative experiences over the past weeks or months. These features pose high risk 
for recall bias and do not allow for examination of fluctuations over small timescales 
(e.g., days).  
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Study 2 found that subjective sleep quality, but not objective sleep quantity or 
quality, was bidirectionally associated with mood on a day-to-day basis. There was also a 
trend for subjective sleep quality from the previous night to predict current subjective 
cognitive functioning. The most interesting finding was the lack of objective sleep effects 
on mood and cognition. In fact, even subjective sleep quantity variables (e.g., subjective 
sleep duration, onset latency, number of awakenings) failed to predict next-day mood and 
cognition. It appears that subjective sleep quality ratings were capturing some other 
factor (e.g., feeling refreshed upon waking) that immediately affects daytime function, or 
the perception of sleep quality itself was affecting daytime function. In the case of either 
explanation, this finding highlights the possibility that psychological mechanisms are 
involved in the interactions between sleep and NMS in PD.  
The main strength of Study 2 was its use of ecological momentary assessment 
(EMA), an intensive repeated measures method that maximizes ecological validity 
(Ebner-Priemer & Trull, 2009), sensitivity to change in symptoms (Moore, Depp, 
Wetherell, & Lenze, 2016b), and statistical power to find temporal associations between 
variables. To our knowledge, this was the first use of electronic EMA in a PD sample. 
Combined with both subjective and objective daily measures of sleep, this study was also 
the first to characterize small-scale temporal relations between NMS in PD.  
The following sections discuss Study 1 and Study 2’ limitations, research and 
clinical implications, and directions for future research. In addition to the NMS measured 
in Studies 1 and 2, there are other possible contributors to the associations between sleep, 
circadian function, cognition, and mood in PD. The first section focuses on two of these 
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additional NMS—depression and daytime sleepiness—and their possible interactions 
with the NMS assessed in this project. The second section considers the potential for 
using electronic EMA in PD. The last section discusses the clinical implications of these 
findings, with a focus on the potential for non-pharmacological interventions for NMS. 
 
Daytime sleepiness and depression 
 Two common and impactful NMS are excessive daytime sleepiness (EDS) and 
depression. EDS affects up to half of individuals with PD (Videnovic & Golombek, 
2013). It includes general difficulty with staying alert during the day and, more rarely 
(6% prevalence), the occurrence of “sleep attacks”—sudden episodes of overwhelming 
sleepiness that pose serious safety risks (e.g., while driving) (Paus et al., 2007). EDS may 
be a prodromal symptom of PD, predicting risk of disease onset threefold (Abbott et al., 
2005). The etiology of EDS is likely multifactorial, including possible contributions from 
PD pathology, aging, and effects of dopamine therapy (Videnovic & Golombek, 2013).  
Clinical intuition suggests that insomnia or sleep deprivation may contribute to 
EDS, but studies of objective sleep and alertness have not found this association in PD 
(Arnulf et al., 2002; Rye et al., 2000). This lack of association indicates that primary 
neurological impairment of arousal systems may contribute to EDS but that a prior 
night’s insomnia symptoms do not. This conceptualization is consistent with our 
understanding of insomnia in the general population (Riedel & Lichstein, 2000). In fact, 
in assessment of insomnia, the presence of EDS is evidence for a differential diagnosis of 
sleep-disordered breathing, narcolepsy, parasomnia, or another neurological disorder. 
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Nevertheless, clinical experience shows that medical professionals and individuals with 
PD often attribute EDS to insomnia. This dysfunctional belief about sleep by those with 
PD increases their daily distress about insomnia, performance anxiety, and 
counterproductive behaviors (e.g., excessive napping), all of which perpetuate insomnia 
(Harvey, 2002).  
One limitation of Study 2 is that it did not assess daily EDS. Future studies should 
take advantage of opportunities to examine any daily temporal associations between 
nocturnal sleep and EDS, as well as associations between EDS and other NMS. If they 
confirm the lack of association between insomnia and EDS on a small timescale, this 
evidence could help to inform our understanding of the complex mechanisms of sleep-
wake impairments in PD, ultimately informing intervention strategies.  
Another NMS that Study 2 did not assess was depression, which is present in 35% 
of those with PD at clinically significant levels (Reijnders et al., 2008). Although some 
have suggested that anxiety affects quality of life more than depression does in PD 
(Yamanishi et al., 2013), depression is nevertheless associated with cognitive symptoms, 
sleep complaints, functioning difficulty, and detriments to quality of life (Reijnders et al., 
2008; Verbaan et al., 2007).  
The association between depression and cognitive function is particularly 
interesting in the context of our present findings. Depression often manifests as 
anhedonia and apathy (another common NMS in PD (den Brok et al., 2015), which is 
associated with low behavioral activation (e.g., sedentary behavior, napping, low 
exposure to bright light). This low activation in turn leads to dampened and disrupted 
  
58 
rest-activity circadian function, which I showed in Study 1 to contribute to worse 
cognitive performance. In this way, the known association between depression and 
cognitive function in PD may be partially mediated by circadian disruption. If this is so, 
alleviating depression may improve circadian function, with downstream benefits for 
cognition. Although Study 2 measured anxiety and positive affect using EMA, these 
constructs are separate from depression and apathy. Future EMA and treatment studies 
should measure depression and apathy directly, which would further elucidate the 
complex associations between NMS. 
 
Potential for using electronic EMA to study NMS 
Study 2 demonstrated that it is feasible to use electronic EMA to study NMS in 
individuals with mild to moderate PD. With small cash incentives, participants completed 
almost all EMA assessments. Minimal trouble-shooting was required of participants and 
research staff to use SymTrend, the smartphone app for EMA data collection. Although 
investigators have long called for greater use of electronic EMA in research with older 
adults (Cain et al., 2009), Study 2 is the first study to test this method’s feasibility in PD.    
Using EMA in PD has several advantages in addition to the general advantages of 
this method (e.g., high ecological validity). First, studying associations between acute 
NMS experiences may yield different results from studying cumulative experience of 
NMS. For example, previous studies have found associations between cumulative sleep 
disturbance and fatigue in PD on the scale of weeks and months (Chung et al., 2013; 
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Neikrug et al., 2013), but I showed that when assessed on a daily basis, neither subjective 
nor objective sleep predicted next-day fatigue.  
Previous studies (including Study 1) have also found that cumulative sleep quality 
over the course of weeks is associated cognitive performance (e.g., Stavitsky et al., 
2012), but Study 2 showed no such associations on a daily scale. It should be noted that 
Study 2 only measured subjective cognition (i.e., asked participants whether they 
experienced cognitive difficulties) and did not measure objective performance on 
neuropsychological tests as in Stavitsky et al., (2012), which may account for the 
difference in findings. Nevertheless, my own exploratory analyses in Study 2 found that 
cumulative sleep duration is correlated with overall subjective cognition (r2 = 0.21, p 
<.01), a pattern not observed using multilevel modeling of EMA data. This suggests that, 
if I had used a traditional approach, I would have at best missed an interesting 
discrepancy between cumulative versus acute sleep effects on cognition, or at worst 
concluded an association that was actually spurious. This is clinically meaningful because 
experience shows that patients often perceive immediate sleep effects (e.g., “my brain fog 
today is due to last night’s insomnia). This is a dysfunctional belief that can exacerbate 
anxiety about sleep, which leads to unhelpful thoughts and behaviors that perpetuate 
sleep disturbance among those with insomnia (Harvey, 2002). Empirical demonstration 
of the contrary, such as in Study 2, could help clinicians to intervene on these beliefs.  
Another advantage of using EMA to study NMS is that small timescale analyses 
can identify mechanisms for temporal associations between variables. For example, in 
cumulative, retrospective self-reports of sleep (e.g., Pittsburg Sleep Quality Index), 
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quantitative variables (e.g., sleep duration) are so subject to recall bias that investigators 
usually aggregate all quantitative and qualitative variables to produce one single sleep 
quality score. In Study 2, participants recalled their quantitative sleep variables within 1 
hour of waking, allowing me greater confidence to use each quantitative/qualitative 
variable (e.g., sleep duration, onset latency, subjective overall quality etc.) as an 
independent predictor. This allowed me to identify subjective sleep quality as a unique 
predictor of next-day mood.  
Finally, studying NMS using EMA paves the way for ecological momentary 
intervention for NMS. Recent studies have used smartphone-delivered interventions to 
improve gait (Pfeiffer et al., 2016) and medication adherence (Lakshminarayana et al., 
2017) In PD. The same approach could be applied to self-management or clinician-
assisted management of NMS. For example, smartphone applications have demonstrated 
feasibility and acceptability for delivering cognitive behavioral therapy for insomnia 
(Koffel et al., 2018) and mood disturbance (Bakker, Kazantzis, Rickwood, & Rickard, 
2016) in the general population. Features of these apps could be adapted for individuals 
with PD. To do so, we need to first assess their daily symptoms of insomnia, anxiety, and 
depression with EMA. Moving towards the development of mobile technology-assisted 
interventions could increase access to care, improve self-management, and ease the 
burden on the health system (Bakker et al., 2016; Lakshminarayana et al., 2017; Pfeiffer 
et al., 2016).  
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Potential of non-pharmacological interventions for treating NMS 
 Because PD has been primarily conceptualized as a motor disorder due to the 
effects of degenerating dopaminergic neurons, treatment research has primarily focused 
on treating motor symptoms with dopamine replacement therapy. As noted earlier, 
however, NMS contribute more to reduction in quality of life than do motor symptoms 
(Martinez-Martin, 2011), and accordingly there is increasing recognition of the need to 
aggressively address NMS (Chaudhuri et al., 2015; Cronin-Golomb, 2013; Willison et al., 
2013). Several pharmacological agents have been tested for excessive sleepiness and 
fatigue but almost none have convincingly demonstrated efficacy (reviewed in Trotti & 
Bliwise, 2014), and those that showed promise also came with US Food and Drug 
Administration “black box” warnings for significant side effects and/or abuse potential 
(Mendonça, Menezes, & Jog, 2007; Ondo et al., 2008). There is some preliminary 
evidence to support doxepin (Romenets et al., 2013), eszopiclone (Menza et al., 2010), 
and quetiapine (Juri, Chaná, Tapia, Kunstmann, & Parrao, 2005) for the treatment of 
insomnia in PD, but again with safety concerns (Trotti & Bliwise, 2014). The safest 
pharmacological treatment for insomnia in PD seems to be melatonin, given its low side-
effect profile, but this drug, too, fails to engender objective sleep changes (Medeiros et 
al., 2007). There is similarly little evidence to support the efficacy and safety of drug 
therapy for mood disturbance (reviewed in Troeung, Egan, & Gasson, 2013) and 
cognitive impairment (reviewed in Svenningsson et al., 2012). Even if effective drugs are 
found, there is concern that cumulative drug treatment for each NMS may not be 
advisable, in light of the already heavy medication burden experienced by persons with 
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PD. Therefore, we need to identify non-pharmacological interventions for addressing 
NMS in PD.  
Circadian and sleep disruption are excellent intervention targets for two reasons. 
First, there already exist effective non-pharmacological treatments for circadian rhythm 
and sleep disorders that are inexpensive and easily disseminated. Second, because the 
circadian and sleep-wake systems are so integrally involved in multiple health domains, 
treating these targets may benefit multiple symptoms. The following sections review 
relevant interventions and their possible circadian/sleep mechanisms of action on NMS. 
 
Bright light therapy. 
Bright light therapy (BLT) is a potential intervention for improving cognitive 
function through its actions on the circadian system. BLT consists of exposure to bright 
light (usually 2500 lux or brighter) at consistent times during the day. Because the master 
clock SCN is entrained to the 24-hour environment through Zeitgebers such as light, 
stabilizing and strengthening this input could help to improve circadian robustness 
(Videnovic et al., 2017). Accordingly, BLT is a standard treatment for irregular sleep-
wake circadian rhythm sleep disorder (Barion & Zee, 2007), a clinical phenotype akin to 
the interdaily instability characterized in Study 1. This approach has also long been 
applied to consolidating and stabilizing rest-activity patterns in individuals with dementia 
(Dowling et al., 2005; Figueiro et al., 2014; Mishima et al., 1994; Riemersma-van der 
Lek et al., 2008; Yamadera et al., 2000). The largest of these studies tested BLT in a 
group care facility, demonstrating that brighter institutional lighting ameliorated 
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cognitive, mood and functional decline over the course of five years (Riemersma-van der 
Lek et al., 2008).  
There is also mounting evidence for BLT’s efficacy for improving sleep and 
mood in PD (e.g., Rutten et al., 2012). Most recently, Videnovic and colleagues 
demonstrated that 14 days of 2-hour daily BLT improved subjective nighttime sleep, 
increased daytime physical activity, and improved daytime sleepiness in PD (Videnovic 
et al., 2017). Although this study did not assess cognition, its pattern of findings supports 
the idea that BLT may improve circadian robustness (e.g., consolidate rest-activity 
patterns). Regarded together with Study 1’s finding that rest-activity interdaily stability 
predicts objective cognitive performance, the findings of Videnovic and colleagues offer 
a promising hint that BLT may be able to improve cognition in PD. Future studies should 
measure cognitive performance as a main outcome of BLT intervention studies. 
 
Exercise and chronotherapy. 
Another potential non-pharmacological approach to improving cognition in PD is 
exercise (Reynolds, Otto, et al., 2016). There is evidence that exercise improves cognitive 
function in healthy older adults (Smith et al., 2010) and in older adults with neurological 
disorders (Forbes, Thiessen, Blake, Forbes, & Forbes, 2013). For individuals with PD, 
aerobic and resistance exercise have demonstrated efficacy for improving executive 
function (Cruise et al., 2011; David et al., 2015; Duchesne et al., 2015; Tanaka et al., 
2009). 
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It is possible that exercise benefits cognition in PD partially through improved 
circadian function. Rodent research shows that behavioral activity increases the 
amplitude of SCN outputs in both young and old mice (Leise et al., 2013; Ramkisoensing 
& Meijer, 2015; van Oosterhout et al., 2012). On a behavioral level, voluntary exercise 
helps mice to synchronize rest-activity and sleep-wake rhythms (Edgar & Dement, 1991; 
Tal-Krivisky, Kronfeld-Schor, & Einat, 2015). In humans, exercise is also a synchronizer 
for the circadian system (Atkinson, Edwards, Reilly, & Waterhouse, 2007; Edwards, 
Reilly, & Waterhouse, 2009), and Study 1 showed that better circadian function predicts 
better cognitive function in PD. Future exercise studies in PD should test the hypothesis 
that circadian improvement is a mechanism for exercise’s effect on cognition. If this is 
the case, exercise may be combined with circadian therapies to maximize this therapeutic 
pathway. For example, chronotherapy and social rhythm therapy use scheduled activities 
(e.g., bed and rise times, social activities, meal times) to shape circadian rhythm and 
strengthen time-of-day signaling (Barion & Zee, 2007). Using timed exercise as part of a 
chronotherapy program could enhance the therapeutic actions of both approaches, with 
possible downstream benefits for cognition.  
 
Cognitive-behavioral therapy. 
 Cognitive-behavioral therapy for insomnia (CBT-I) has potential to improve sleep 
and mood in PD. CBT-I is a multicomponent treatment that includes sleep-wake behavior 
change to regulate sleep homeostatic drive and decrease arousal, and cognitive therapy to 
decrease anxiety and dysfunctional thoughts that maintain insomnia (Morin, 2006). There 
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is strong evidence that CBT-I is effective for both primary insomnia (Trauer, Qian, 
Doyle, Rajaratnam, & Cunnington, 2015) and insomnia comorbid with another medical 
or psychiatric disorder (Wu, Appleman, Salazar, & Ong, 2015). There is preliminary 
evidence that CBT-I can also improve sleep in PD, although the only clinical trial of 
CBT-I in PD combined it with light therapy (Romenets et al., 2013). More investigation 
is needed not only to examine CBT-I’s independent efficacy, but also to measure other 
NMS (e.g., cognition, mood) as outcomes. Considering Study 2’s finding that subjective 
sleep quality in PD has immediate effects on anxiety (and to a lesser extent, subjective 
cognition), improving sleep perception has the potential to improve daytime functioning.  
 The cognitive therapy component of CBT-I may be particularly important for 
improving mood in PD. Study 2 found that objective sleep variables (and even subjective 
quantitative sleep variables) did not affect mood on a day-to-day basis, which highlights 
the importance of psychological factors in daily sleep-mood associations in PD. Aitken et 
al. (2014) found that dysfunctional beliefs about sleep (e.g., “I must have eight hours of 
sleep to be healthy”) were associated with mood disturbance, whereas objective sleep 
variables were not. The cognitive therapy in CBT-I uses psychoeducation and Socratic 
questioning to challenge dysfunctional beliefs, which decreases performance anxiety and 
general anxiety related to sleep (Harvey, 2002). Study 2 found that daytime mood also 
affects later sleep in PD, suggesting that addressing dysfunctional beliefs may begin a 
positive cycle of mutually improving sleep and mood.  
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Conclusion 
The two studies described here contributed to research on PD through their 
innovative methods and their focus on neglected areas of inquiry. Study 1 investigated 
circadian rest-activity rhythm’s association with cognitive performance in PD, and found 
that interdaily stability of rhythms predicts executive, visuospatial, and psychomotor 
function independently of sleep. Study 2 used an intensive repeated-measures approach to 
explore temporal associations between sleep and daytime symptoms in PD. Its findings 
highlight the different relations of subjective and objective sleep to mood, as well as the 
utility and feasibility of measuring sleep and daytime function on a small timescale.  
Non-motor symptoms in PD continue to receive less attention than motor 
symptoms in research and clinical practice (Chaudhuri et al., 2011; Cronin-Golomb, 
2013), despite their ubiquity and impact (Barone et al., 2009; Chaudhuri et al., 2006; 
Martinez-Martin, 2011). Among them, sleep and circadian disruption, mood disturbance, 
and cognitive impairment are particularly common and distressing (Aarsland et al., 2017; 
Duncan et al., 2014; Reijnders et al., 2008; Reynolds, Barlow, et al., 2016). The findings 
presented here describe associations between these symptoms in novel ways, including 
their daily bidirectional interactions. These findings also contribute to the growing 
interest in characterizing circadian function in PD, which holds promise as a novel 
treatment target (Videnovic et al., 2017; Videnovic & Willis, 2016).  
With improved understanding of sleep and circadian function in PD, we could 
shed light on systems that play integral roles in multiple disease processes. As potential 
treatment targets, they offer an opportunity to “raise the water for all boats.” Future work 
  
67 
should begin to explore non-pharmacological interventions such as bright light therapy, 
exercise, and cognitive-behavioral therapy for improving circadian and sleep function, 
which may, in turn, reduce a range of other symptoms. Future efforts should also aim to 
develop and disseminate these interventions using mobile technology in order to increase 
access and adherence to care, with the ultimate goal of improving quality of life for 
individuals with PD. 
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